Results & Financial lifeHealthcare - Pharma - Biotech
GENFIT Highlights Data from Clinical Studies of Nangibotide, Supporting Its Advancement into ACLF with Phase 2 Data Expected in 2027
09/11/2026 07:30
AMFImmediate publication
Lille (France), Cambridge (Massachusetts, United States), November 9, 2026 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, yesterday unveiled an in-depth review of nangibotide, its new lead asset in…
GENFIT | 885 Avenue Eugène Avinée, 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com 1
PRESS RELEASE
GENFIT Highlights Data from Clinical Studies of Nangibotide,
Supporting Its Advancement into ACLF with Phase 2 Data
Expected in 2027
- Comprehensive clinical and scientific data supporting Phase 2 development of nangibotide in ACLF unveiled to leading experts during AASLD The Liver Meeting®
- Strong biological rationale in ACLF: TREM-1 modulation is designed to dampen excessive inflammatory amplification without directly targeting immune recognition
- Prior Phase 2 clinical evidence demonstrated a well-characterized safety profile, efficacy signals in a subgroup of patients from septic shock trial, improved clinical status and lower mortality in patients with severe COVID-19
- UPWARD Phase 2a proof-of-concept trial expected to be initiated by end of 2026, data expected second half of 2027
Lille (France), Cambridge (Massachusetts, United States), November 9, 2026 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, yesterday unveiled an in-depth review of nangibotide, its new lead asset in acute-on-chronic liver failure (ACLF), during a scientific event gathering leading ACLF experts in Denver during AASLD The Liver Meeting®.
Professor Jennifer C. Lai, MD, MBA, Transplant Hepatologist, Endowed Professor of Liver Health & Transplantation, University of California, San Francisco (UCSF) commented: “The unmet need in ACLF remains tremendous, particularly for patients in the ICU who can rapidly progress to multi-organ failure. What is especially exciting about nangibotide is that we are not starting from scratch: the program already benefits from substantial Phase 2 clinical experience and proof-of-concept in acute inflammatory conditions characterized by organ dysfunction. This gives us a rare opportunity to bring an already extensively studied clinical-stage candidate into ACLF and explore whether those signals can translate into meaningful benefit for these critically ill patients.”
Strong biological rationale for TREM-1 modulation in ACLF
ACLF presents a major therapeutic challenge: controlling excessive systemic inflammation, a key driver of organ failure, without further compromising an already dysfunctional immune response. By modulating TREM-1, an amplifier of inflammation, nangibotide is designed to dampen excessive inflammatory amplification without directly targeting immune recognition itself. GENFIT | 885 Avenue Eugène Avinée, 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com 2
PRESS RELEASE